Alpha-GABa receptor modulators for the treatment of cognitive impairment associated with Huntington’s disease

People with Huntington’s disease lose their ability to think clearly years before their movement problems become obvious, and no drug exists to slow or reverse that decline. Huntington’s disease is a fatal genetic condition that attacks movement, mood, and memory. The cognitive decline—difficulty concentrating, planning, and remembering—often starts a decade before diagnosis and is a major cause of disability. Yet current treatments focus only on movement symptoms, leaving a large gap in care. Professor John Atack at the University of Sussex is searching for drugs that can boost cognitive performance in people with Huntington’s disease. If successful, this research could produce the first treatment specifically for the cognitive symptoms of Huntington’s disease. That would mean people could stay independent, hold conversations, and manage daily tasks for longer. It would also open a new avenue for treating cognitive decline in other brain disorders where similar brain circuits are damaged. The work is at an early, drug-discovery stage, so a usable treatment is years away—but the need is immediate and the target is clear.